Brunel University Research Archive(BURA) preserves and enables easy and open access to all
types of digital content. It showcases Brunel's research outputs.
Research contained within BURA is open access, although some publications may be subject
to publisher imposed embargoes. All awarded PhD theses are also archived on BURA.
Browsing by Author Hall, M
Showing results 1 to 20 of 32
next >
| Issue Date | Title | Author(s) |
|---|---|---|
| 7-Sep-2021 | Circulating tumour cells and circulating cell-free DNA in lung cancer patients: A comparison between Thoracotomy and Video-Assisted Thoracoscopic Surgery | Katopodis, P; Anikin, V; Kishore, U; Carter, T; Hall, M; Asadi, N; Polychronis, A; Karteris, E |
| 26-Feb-2021 | COVID‑19 and SARS‑CoV‑2 host cell entry mediators: Expression profiling of TMRSS4 in health and disease | Katopodis, P; Kerslake, R; Davies, J; Randeva, HS; Chatha, K; Hall, M; Spandidos, DA; Anikin, V; Polychronis, A; Robertus, JL; Kyrou, I; Karteris, E |
| 2020 | Co‑expression of peripheral olfactory receptors with SARS‑CoV‑2 infection mediators: Potential implications beyond loss of smell as a COVID‑19 symptom | Kerslake, R; Hall, M; Randeva, H; Spandidos, D; Chatha, K; Kyrou, I; Karteris, E |
| 25-Mar-2023 | Description of a Retrospective Cohort of Epithelial Ovarian Cancer Patients with Brain Metastases: Evaluation of the Role of PARP Inhibitors in this Setting | Alizzi, Z; Roxburgh, P; Cartwright, D; McLaren, A; Park, S; Jones, R; Greening, S; Hudson, E; Green, C; Gray, S; Khalique, S; Karteris, E; Hall, M |
| 17-Jul-2019 | Detection of Abundant Non-Haematopoietic Circulating Cancer-Related Cells in Patients with Advanced Epithelial Ovarian Cancer | Kumar, J; Chudasama, D; Charlotee, R; Kubista, M; Sjoback, R; Chatterjee, J; Anikin, V; Karteris, E; Hall, M |
| 15-Jun-2023 | Development of a dual energy CT based model to assess response to treatment in patients with high grade serous ovarian cancer: a pilot cohort study | Alizzi, Z; Gogbashian, A; Karteris, E; Hall, M |
| 2016 | Differential effects of rapalogues, dual kinase inhibitors on human ovarian carcinoma cells in vitro | Rogers-Broadway, KR; Chudasama, D; Pados, G; Tsolakidis, D; Goumenou, A; Hall, M; Karteris, E |
| 31-Oct-2018 | Differential expression of mTOR components in endometriosis and ovarian cancer: Effects of rapalogues and dual kinase inhibitors on mTORC1 and mTORC2 stoichiometry | Rogers‑Broadway, KR; Kumar, J; Sisu, C; Wander, G; Mazey, E; Jeyaneethi, J; Pados, G; Tsolakidis, D; Klonos, E; Grunt, T; Hall, M; Chatterjee, J; Karteris, E |
| 1-Feb-2022 | Differential Expression of RAD51AP1 in Ovarian Cancer: Effects of siRNA In Vitro | Filipe, A; Chudasama, D; Kerslake, R; Jeyaneethi, J; Anikin, V; Kyrou, I; Randeva, H; Sisu, C; Hall, M; Karteris, E |
| 8-Oct-2022 | Differential Regulation of Genes by the Glucogenic Hormone Asprosin in Ovarian Cancer | Kerslake, R; Sisu, C; Panfilov, S; Hall, M; Khan, N; Jeyaneethi, J; Randeva, H; Kyrou, I; Karteris, E |
| 24-Jul-2017 | Discovery and replication of SNP-SNP interactions for quantitative lipid traits in over 60,000 individuals | Holzinger, ER; Verma, SS; Moore, CB; Hall, M; De, R; Gilbert-Diamond, D; Lanktree, MB; Pankratz, N; Amuzu, A; Burt, A; Dale, C; Dudek, S; Furlong, CE; Gaunt, TR; Kim, DS; Riess, H; Sivapalaratnam, S; Tragante, V; Van Iperen, EPA; Brautbar, A; Carrell, DS; Crosslin, DR; Jarvik, GP; Kuivaniemi, H; Kullo, IJ; Larson, EB; Rasmussen-Torvik, LJ; Tromp, G; Baumert, J; Cruickshanks, KJ; Farrall, M; Hingorani, AD; Hovingh, GK; Kleber, ME; Klein, BE; Klein, R; Koenig, W; Lange, LA; MOrz, W; North, KE; Charlotte Onland-Moret, N; Reiner, AP; Talmud, PJ; Van Der Schouw, YT; Wilson, JG; Kivimaki, M; Kumari, M; Moore, JH; Drenos, F; Asselbergs, FW; Keating, BJ; Ritchie, MD |
| 2015 | Edoxaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation: A Single Technology Appraisal. Evidence Review Group Report to NICE | Greenhalgh, J; Longworth, L; Crossan, C; Singh, J; Bagust, A; Beale, S; Richardson, M; Banks, L; Kotas, E; Hall, M |
| 2024 | Effect of MYC and PARP Inhibitors in Ovarian Cancer Using an In Vitro Model | Morea, A; Saravi, S; Sisu, C; Hall, M; Tosi, S; Storlazzi, CT; Karteris, E |
| 27-Dec-2022 | Elevated Circulating Lactate Levels and Widespread Expression of Its Cognate Receptor, Hydroxycarboxylic Acid Receptor 1 (HCAR1), in Ovarian Cancer | Kerslake, R; Panfilov, S; Mustafa, N; Hall, M; Kyrou, I; Randeva, H; Karteris, E; Godfrey, R |
| 2-Sep-2020 | H2A Histone Family Member X (H2AX) Is Upregulated in Ovarian Cancer and Demonstrates Utility as a Prognostic Biomarker in Terms of Overall Survival | Saravi, S; Katsuta, E; Jeyaneethi, J; Amin, HA; Kaspar, M; Takabe, K; Pados, G; Drenos, F; Hall, M |
| 10-Aug-2020 | Identification of Cancer-Associated Circulating Cells in Anal Cancer Patients | Carter, TJ; Jeyaneethi, J; Kumar, J; Karteris, E; Glynne-Jones, R; Hall, M |
| 8-Nov-2017 | Identification of novel cancer biomarkers of prognostic value using specific gene regulatory networks (GRN): a novel role of RAD51AP1 for ovarian and lung cancers | Chudasama, D; Bo, V; Hall, M; Anikin, V; Jeyaneethi, J; Gregory, J; Pados, G; Tucker, A; Harvey, A; Pink, R; Karteris, E |
| 5-May-2021 | Identification of Potential Bisphenol A (BPA) Exposure Biomarkers in Ovarian Cancer | Zahra, A; Dong, Q; Hall, M; Jeyaneethi, J; Silva, E; Karteris, E; Sisu, C |
| 4-Aug-2023 | Identification of RAD51 foci in cancer-associated circulating cells of patients with high-grade serous ovarian cancer: Association with treatment outcomes | Alizzi, Z; Saravi, S; Khalique, S; Mcdonald, T; Karteris, E; Hall, M |
| 15-Nov-2016 | Identifying gene–gene interactions that are highly associated with four quantitative lipid traits across multiple cohorts | De, R; Verma, SS; Holzinger, E; Hall, M; Burt, A; Carrell, DS; Crosslin, DR; Jarvik, GP; Kuivaniemi, H; Kullo, IJ; Lange, LA; Lanktree, MB; Larson, EB; North, KE; Reiner, AP; Tragante, V; Tromp, G; Wilson, JG; Asselbergs, FW; Drenos, F; Moore, JH; Ritchie, MD; Keating, B; Gilbert-Diamond, D |